NDA 206488 · Sarepta Theraps INC
Exondys 51
Eteplirsen · Intravenous · Antisense Oligonucleotide
NovelAccelerated approvalPriority reviewOrphanLast checked: Nov 20, 2026Latest source record: Dec 27, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2016
Sep 19, 2016
Approved uses
1
Original approval plus efficacy supplements
Registered trials
11
2 Phase 3, 0 recruiting
FAERS reports
2,414
495 serious, 68 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Aug 13, 2025.
EXONDYS 51 is indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation of the DMD gene that is amenable to exon 51 skipping. This indication is approved under accelerated approval based on an increase in dystrophin in skeletal muscle observed in some patients treated with EXONDYS 51 [see Clinical Studies ( 14 )] . Continued approval for this indication may be contingent upon verification of a clinical benefit in confirmatory trials. EXONDYS 51 is an antisense oligonucleotide indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation of the DMD gene that is amenable to exon 51 skipping. This indication is approved under accelerated approval based on an increase in dystrophin in skeletal muscle observed in some patients treated with EXONDYS 51 [see Clinical Studies ( 14 )]. Continued approval for this indication may be contingent upon verification of a clinical benefit in confirmatory trials. ( 1 )
Mechanism: Eteplirsen is designed to bind to exon 51 of dystrophin pre-mRNA, resulting in exclusion of this exon during mRNA processing in patients with genetic mutations that are amenable to exon 51 skipping. Exon skipping is intended to allow for production of an internally truncated dystrophin protein, which was evaluated in Study 2 and Study 3 [ see Clinical Studies ( 14 ) ].
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Sep 19, 2016 Original approval · Type 1 - New Molecular Entity · priority review NovelAccelerated approvalOrphanLetterLabelSummary Review
2 products under this application
- EXONDYS 51 · ETEPLIRSEN 500MG/10ML (50MG/ML) · SOLUTION, INTRAVENOUS · Prescription
- EXONDYS 51 · ETEPLIRSEN 100MG/2ML (50MG/ML) · SOLUTION, INTRAVENOUS · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Eteplirsen" as an intervention, any sponsor and status, largest first.
- A Study to Compare Safety and Efficacy of High Doses of Eteplirsen in Participants With Duchenne Muscular Dystrophy (DMD) (MIS51ON)Pivotal-lookingCompleted
Sarepta Therapeutics, Inc.Industry
NCT03992430 · 160 participants · Start Jul 13, 2020 · Primary completion Sep 7, 2026
Drug: Eteplirsen · For: Muscular Dystrophy, Duchenne
Sites: Birmingham, Alabama; Gainesville, Florida; Atlanta, Georgia · 59 sites in all
- Study of Eteplirsen in DMD PatientsPivotal-lookingCompleted
Sarepta Therapeutics, Inc.Industry
NCT02255552 · 109 participants · Start Nov 17, 2014 · Primary completion Jun 14, 2019
Drug: eteplirsen · For: Duchenne Muscular Dystrophy (DMD)
Sites: Phoenix, Arizona; Los Angeles, California; Sacramento, California · 37 sites in all
Sarepta Therapeutics, Inc.Industry
NCT02420379 · 33 participants · Start Jun 30, 2015 · Primary completion Dec 17, 2018
Drug: eteplirsen · For: Duchenne Muscular Dystrophy (DMD)
Sites: Phoenix, Arizona; Los Angeles, California; Sacramento, California · 13 sites in all
Sarepta Therapeutics, Inc.Industry
NCT02286947 · 24 participants · Start Nov 2014 · Primary completion Apr 21, 2017
Drug: Eteplirsen · For: Muscular Dystrophy, Duchenne
Sites: Los Angeles, California; Sacramento, California; Iowa City, Iowa · 9 sites in all
Sarepta Therapeutics, Inc.Industry
NCT00844597 · 19 participants · Start Jan 2009 · Primary completion Jun 2010
Drug: AVI-4658 for Injection · For: Duchenne Muscular Dystrophy
Sites: London, United Kingdom; Newcastle upon Tyne, United Kingdom
Sarepta Therapeutics, Inc.Industry
NCT03985878 · 15 participants · Start Jun 26, 2019 · Primary completion Aug 31, 2022
Drug: Eteplirsen · For: Duchenne Muscular Dystrophy
Sites: Ghent, Belgium; Paris, France; Rome, Italy · 4 sites in all
Sarepta Therapeutics, Inc.Industry
NCT03218995 · 15 participants · Start Aug 16, 2017 · Primary completion Mar 10, 2021
Drug: Eteplirsen · For: Duchenne Muscular Dystrophy
Sites: Ghent, Belgium; Paris, France; Roma, Italy · 4 sites in all
Sarepta Therapeutics, Inc.Industry
NCT01396239 · 12 participants · Start Jul 2011 · Primary completion Feb 2012
Drug: AVI-4658 (Eteplirsen) · For: Duchenne Muscular Dystrophy
Sites: Columbus, Ohio
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- product dose omission issue697
- no adverse event550
- intentional dose omission279
- poor venous access187
- device issue182
- pyrexia110
- covid-1987
- malaise74
- pneumonia64
- fall62
- cough56
- illness55
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2016 | 2 |
| 2017 | 48 |
| 2018 | 223 |
| 2019 | 155 |
| 2020 | 193 |
| 2021 | 255 |
| 2022 | 246 |
| 2023 | 387 |
| 2024 | 340 |
| 2025 | 325 |
| 2026 | 240 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Exondys-51 (Eteplirsen)
2024 spending
$26.8M
Beneficiaries
18
440 claims
Per beneficiary
$1,488,217
$811.57 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $15,420,573 |
| 2021 | $18,738,226 |
| 2022 | $25,522,809 |
| 2023 | $24,497,663 |
| 2024 | $26,787,913 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Eteplirsen for the treatment of Duchenne muscular dystrophy.
Mendell JR, Rodino-Klapac LR, Sahenk Z, et al. · Ann Neurol 2013 · Randomized Controlled Trial, Research Support, N.I.H., Extramural
- Predictors of Loss of Ambulation in Duchenne Muscular Dystrophy: A Systematic Review and Meta-Analysis.
Landfeldt E, Alemán A, Abner S, et al. · J Neuromuscul Dis 2024 · Systematic Review, Meta-Analysis
- Absorption, Distribution, Metabolism, and Excretion of US Food and Drug Administration-Approved Antisense Oligonucleotide Drugs.
Migliorati JM, Liu S, Liu A, et al. · Drug Metab Dispos 2022 · Meta-Analysis, Review
- Open-Label Evaluation of Eteplirsen in Patients with Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping: PROMOVI Trial.
McDonald CM, Shieh PB, Abdel-Hamid HZ, et al. · J Neuromuscul Dis 2021 · Clinical Trial, Phase III, Multicenter Study
- Clinical Phenotypes of DMD Exon 51 Skip Equivalent Deletions: A Systematic Review.
Waldrop MA, Yaou RB, Lucas KK, et al. · J Neuromuscul Dis 2020 · Systematic Review
- Exon skipping for Duchenne muscular dystrophy: a systematic review and meta-analysis.
Shimizu-Motohashi Y, Murakami T, Kimura E, et al. · Orphanet J Rare Dis 2018 · Meta-Analysis, Research Support, Non-U.S. Gov't
Sponsor: Sarepta Theraps INC
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.